Argomenti trattati
The Muscular Dystrophy Association (MDA) is preparing for its annual Clinical & Scientific Conference, a key event that gathers researchers, healthcare professionals, and advocates to address neuromuscular diseases. This year’s conference will take place from March 8 to March 11, 2026, in Orlando, Florida. It will feature John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), as the keynote speaker.
As the largest global event dedicated to neuromuscular issues, the conference is designed to encourage collaboration and innovation among diverse stakeholders. Crowley’s keynote address, scheduled for March 9 at 9:30 am ET, is anticipated to provide valuable insights into the future of biotechnology and patient care.
John F. Crowley’s vision for biotechnology
In his upcoming presentation titled Driving the future of innovation, policy, and patient impact, Crowley will explore the transformative role of biotechnology in medical research. He will highlight the importance of patient-driven advocacy and emerging technologies in reshaping healthcare.
The role of advocacy in biotechnology
Crowley asserts that the collaboration between patients and biotechnology companies is vital for advancing treatment options for rare diseases. He notes that we are experiencing a significant period for biotechnology, where data-driven approaches and partnerships can lead to innovative therapies that enhance lives. The Muscular Dystrophy Association (MDA) has been instrumental in this evolution, supporting research and fostering a community focused on improving patient outcomes.
Sharon Hesterlee, PhD, President and CEO of the MDA, emphasized the journey of Crowley, who transformed from a father determined to save his children diagnosed with Pompe disease into a leader in biotechnology. His personal experiences drive his dedication to patient advocacy and innovation, making his insights particularly valuable for attendees.
A legacy of innovation at MDA
The MDA has played a crucial role for 75 years, providing resources and support for individuals affected by muscular dystrophy and other neuromuscular conditions. Crowley’s participation in the conference highlights the organization’s ongoing mission to expand the frontiers of medical science.
What to expect at the conference
Participants can expect extensive knowledge-sharing opportunities at the conference, which anticipates over 2,500 attendees. This group will include prominent researchers, clinicians, and industry leaders. The event will offer a range of sessions, with dedicated tracks focusing on the latest advancements in neuromuscular research. The previous year featured 39 sessions and more than 200 speakers, highlighting the dynamic exchange of ideas that defines this gathering.
Moreover, the conference will provide valuable networking opportunities, fostering collaboration among professionals committed to treating neuromuscular diseases. Such exchanges are crucial for driving innovation and speeding up the development of new therapies.
Getting involved
Registration now open for MDA conference
Individuals interested in attending can register for both in-person and virtual participation at MDAConference.org. Early bird registration remains available until December 31, offering attendees the opportunity to secure their place at this important event.
The Muscular Dystrophy Association (MDA) is actively interacting with its community on social media platforms. Updates are shared, and discussions are encouraged using the hashtag #MDAconference. This outreach not only promotes the conference but also fosters a sense of community among individuals affected by neuromuscular diseases.
A landmark event for MDA’s 75th anniversary
As the MDA marks its 75th anniversary, the upcoming conference is set to be a significant occasion, highlighting advancements in understanding and treating neuromuscular conditions. Keynote speaker John F. Crowley is expected to inspire attendees, motivating them to advance their crucial work in this field.
For additional details, including a comprehensive list of sponsors and exhibitors, interested individuals can contact us via email at [email protected].